Format

Send to

Choose Destination
Support Care Cancer. 2016 Mar;24(3):1071-8. doi: 10.1007/s00520-015-2876-5. Epub 2015 Aug 8.

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.

Author information

1
Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
2
Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
3
Washington University School of Medicine, St. Louis, MO, USA.
4
Cancer Center of Kansas, Wichita, KS, USA.
5
Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. cloprinzi@mayo.edu.

Abstract

PURPOSE:

Previous pilot data suggested that venlafaxine could prevent acute and chronic oxaliplatin-related neuropathy. The purpose of this randomized, placebo-controlled, double-blinded pilot study was to obtain additional data to support conducting a phase III trial to test the use of venlafaxine to prevent oxaliplatin neurotoxicity.

METHODS:

Fifty patients, scheduled to undergo oxaliplatin-based therapy (FOLFOX) for stages II-III (67%) or stage IV (33%) colon cancer, were randomized to receive venlafaxine extended release (37.5 mg) or placebo, twice daily, through their last dose of oxaliplatin and then titrated off. Neurotoxicity was evaluated via several patient- and physician-reported measures, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20) instrument.

RESULTS:

Baseline patient characteristics were equivalent for the two arms, with a median age of 60 years. There was a trend toward benefit for the venlafaxine arm, when evaluated by the oxaliplatin-specific neuropathy scale and by acute neuropathy measures of throat discomfort and discomfort swallowing cold liquids, the latter only for the first two oxaliplatin doses. These trends were outweighed by a lack of any such trends in all other measurements including the following: (1) the CIPN20 sensory subscale (Pā€‰=ā€‰0.55, primary endpoint), physician-completed NCI CTCAE assessment, or cumulative administered oxaliplatin doses (median 716 vs 631 mg for placebo and venlafaxine, respectively, Pā€‰=ā€‰0.34).

CONCLUSIONS:

The present study neither supports the use of venlafaxine for preventing oxaliplatin-induced neuropathy in clinical practice nor the initiation of a phase III trial to investigate venlafaxine in this setting.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01611155.

KEYWORDS:

Chemotherapy-induced neuropathy prevention; Venlafaxine

PMID:
26248652
PMCID:
PMC4939800
[Available on 2017-03-01]
DOI:
10.1007/s00520-015-2876-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center